Drugs for Lung Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 103)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Afatinib |
Approved |
Phase 4 |
|
439081-18-2, 850140-72-6 |
53445376 10184653 |
Synonyms:
AFATINIB
AFATINIBUM
BIBW 2992
BIBW2992
BIBW-2992
|
BIBW2992|Gilotrif®
GILOTRIF
GIOTRIF
Tomtovok
Tovok
|
|
2 |
|
Nedaplatin |
Approved, Investigational |
Phase 4 |
|
95734-82-0 |
|
Synonyms:
(glycolato-O,O')diammineplatinum(II)
CDGP
cis-Diammine (glycolato)platinum
|
cis-diammine(glycolato)platinum
cis-Diammine(glycolato)platinum(II)
Nedaplatin
|
|
3 |
|
Rivoceranib |
Investigational |
Phase 4 |
|
811803-05-1 |
11315474 |
Synonyms:
APATINIB
apatinib (in China)|YN968D1
Apatinib mesylate
Rivoceranib
|
Rivoceranib mesylate
YN968D1
YN968D1 free base
|
|
4 |
|
Gemcitabine |
Approved |
Phase 3 |
|
95058-81-4, 122111-03-9 |
60750 |
Synonyms:
2',2'-DFDC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
DDFC
DFDC
DFdCyd
Gemcin
GEMCITABIN
Gemcitabina
Gemcitabina [INN-Spanish]
GEMCITABINE
GEMCITABINE HCL
|
Gemcitabine hydrochloride
gemcitabine hydrochloride|Gemzar®
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
GEO
INFUGEM
LY188011
LY-188011
LY188011 HYDROCHLORIDE
LY-188011 HYDROCHLORIDE
NSC-613327
|
|
5 |
|
Durvalumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
1428935-60-7 |
|
Synonyms:
|
6 |
|
Palbociclib |
Approved, Investigational |
Phase 2, Phase 3 |
|
571190-30-2 |
5330286 |
Synonyms:
6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-D)pyrimidin-7-one
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-{[5-(PIPERAZIN-1-YL)PYRIDIN-2-YL]AMINO}PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
IBRANCE
Ibrance®|PD-0332991|PD0332991
PALBOCICLIB
|
PD 0332991
PD 332991
PD0332991
PD-0332991
UNII-g9Zf61le7g
|
|
7 |
|
Gefitinib |
Approved, Investigational |
Phase 3 |
|
184475-35-2 |
123631 |
Synonyms:
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
GEFITINIB
Gefitinibum
Iressa
Iressa®|ZD 1839|ZD1839
Irressat
|
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
ZD 1839
ZD1839
ZD-1839
|
|
8 |
|
Vinorelbine |
Approved, Investigational |
Phase 3 |
|
71486-22-1 |
44424639 60780 |
Synonyms:
5' Nor anhydrovinblastine
5'-Noranhydrovinblastine
5'-Nor-anhydrovinblastine
Navelbine
Navelbine Base
Vinorelbin
Vinorelbina
Vinorelbina [Spanish]
|
Vinorelbine
VINORELBINE BASE
Vinorelbine bitartrate
Vinorelbine ditartarate
Vinorelbine ditartrate
Vinorelbine tartrate
Vinorelbinum
Vinorelbinum [Latin]
|
|
9 |
|
Bevacizumab |
Approved, Investigational |
Phase 3 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
10 |
|
Ipilimumab |
Approved |
Phase 3 |
|
477202-00-9 |
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
11 |
|
Cetuximab |
Approved |
Phase 3 |
|
205923-56-4 |
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
12 |
|
Erlotinib |
Approved, Investigational |
Phase 2, Phase 3 |
|
183319-69-9, 183321-74-6 |
176870 |
Synonyms:
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
[6,7-Bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine
11C Erlotinib
11C-Erlotinib
CP-358
CP-358,774
CP-358774
CP-35877401
CP-358774-01
ERLOTINIB
Erlotinib HCL
Erlotinib hydrochloride
Erlotinibum
|
HCL, Erlotinib
Hydrochloride, erlotinib
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
NSC 718781
NSC 718781|OSI 744|OSI-774|R 1415|Tarceva®
OSI 744
OSI 774
OSI-774
R 1415
R-1415
RG-1415
RO-508231
Tarceva
|
|
13 |
|
Iniparib |
Investigational |
Phase 3 |
|
160003-66-7 |
9796068 |
Synonyms:
4-iodo-3-nitrobenzamide
4-Iodo-3-nitrobenzene-1-carboximidate
BSI 201
|
BSI-201
Iniparib
SAR240550
|
|
14 |
|
Rilotumumab |
Investigational |
Phase 2, Phase 3 |
|
872514-65-3 |
|
Synonyms:
|
15 |
|
Endostar protein |
|
Phase 3 |
|
|
|
16 |
|
Endostatins |
|
Phase 3 |
|
|
|
17 |
|
Antimetabolites |
|
Phase 3 |
|
|
|
18 |
|
Poly(ADP-ribose) Polymerase Inhibitors |
|
Phase 3 |
|
|
|
19 |
|
Shark Cartilage |
|
Phase 3 |
|
|
|
20 |
|
Angiogenesis Inhibitors |
|
Phase 3 |
|
|
|
21 |
|
Immunoglobulin G |
|
Phase 3 |
|
|
|
22 |
|
Endothelial Growth Factors |
|
Phase 3 |
|
|
|
23 |
|
Mitogens |
|
Phase 3 |
|
|
|
24 |
|
Antineoplastic Agents, Immunological |
|
Phase 2, Phase 3 |
|
|
|
25 |
|
Protein Kinase Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
26 |
|
Immunoglobulins, Intravenous |
|
Phase 2, Phase 3 |
|
|
|
27 |
|
Immunoglobulins |
|
Phase 2, Phase 3 |
|
|
|
28 |
|
Antibodies, Monoclonal |
|
Phase 2, Phase 3 |
|
|
|
29 |
|
Antibodies |
|
Phase 2, Phase 3 |
|
|
|
30 |
|
Treosulfan |
Approved, Investigational |
Phase 2 |
|
299-75-2 |
9296 |
Synonyms:
(2S,3S)-Threitol 1,4-bismethanesulfonate
1,4-Dimethanesulfonate(2S,3S)-threitol
1,4-Dimethanesulfonatel-(+ )-threitol
1,4-Dimethanesulfonatel-threitol
2,3-Dihydroxy-4-(methanesulfonyloxy)butyl methanesulfonic acid
2,3-Dihydroxy-4-(methanesulphonyloxy)butyl methanesulphonate
2,3-Dihydroxy-4-(methanesulphonyloxy)butyl methanesulphonic acid
DHB
Dihydroxybusulfan
Dihydroxymyleran
L-Dihydroxybusulfan
L-Threitol 1,4-dimethanesulfonate
L-Threitol, 1, 4-bis(methanesulfonate)
|
L-Threitol-1, 4-bis(methanesulfonate)
L-Threitol-1,4-bis(methanesulfonate)
L-Threitol-1,4-bismethanesulfonate
L-Threityl dimesylate
OVASTAT
Treosulfan
Treosulfan, ((r*,r*)-(+-))-isomer
Treosulfan, (R-(r*,r*))-isomer
Treosulfan, (r*,r*)-isomer
Treosulfan, (r*,s*)-isomer
Treosulphan
Tresulfan
|
|
31 |
|
Clarithromycin |
Approved |
Phase 2 |
|
81103-11-9 |
84029 |
Synonyms:
6-O-METHYL ERYTHROMYCIN
6-O-Methylerythromycin
6-O-Methylerythromycin a
A-56268
ABBOTT-56268
Biaxin
BIAXIN XL
BIAXIN XL PAC
CAM
CLA
CLARIE XL
CLARITHROMYCIN
CLARITHROMYCIN EXTENDED RELEASE
CLARITHROMYCIN IDENTITY
Clarithromycina
Clarithromycine
|
Clarithromycinum
Claritromicina
CLAROSIP
Clathromycin
FEBZIN XL
KLARICID
KLARICID 500
KLARICID ADULT
KLARICID I.V.
KLARICID PAED
KLARICID XL
MYCIFOR XL
PREVPAC
TE-031
XETININ XL
ZECLAR
|
|
32 |
|
Pioglitazone |
Approved, Investigational |
Phase 2 |
|
111025-46-8 |
4829 |
Synonyms:
(+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(±)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
5-{4-[2-(5-ETHYLPYRIDIN-2-YL)ETHOXY]BENZYL}-1,3-THIAZOLIDINE-2,4-DIONE
Actos
Actos®|Glustin®|pioglitazone HCl|U-72107A
Actost
AD-4833
DUETACT
Glustin
Pioglitazona
Pioglitazona [INN-Spanish]
|
PIOGLITAZONE
Pioglitazone [Ban:Inn]
Pioglitazone HCL
Pioglitazone hydrochloride
Pioglitazonum
Pioglitazonum [INN-Latin]
Poglitazone hydrochloride
U-72107
U-72107A
XAB907
ZACTOS
|
|
33 |
|
Docetaxel |
Approved, Investigational |
Phase 2 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
34 |
|
Talazoparib |
Approved, Investigational |
Phase 2 |
|
1207456-01-6 |
135565082 |
Synonyms:
BMN 673
BMN-673
BMN-673|BMN673|Talzenna®
|
LT-673
TALAZOPARIB
Talzenna
|
|
35 |
|
Tremelimumab |
Approved, Investigational |
Phase 2 |
|
745013-59-6 |
|
Synonyms:
CP-675,206
CP-675|CP-675,206|CP-675206|ticilimumab
CP-675206
|
TICILIMUMAB
TREMELIMUMAB
TREMELIMUMAB (GENETICAL RECOMBINATION)
|
|
36 |
|
Ceritinib |
Approved |
Phase 2 |
|
1032900-25-6 |
57379345 |
Synonyms:
2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2- isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine
5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
CERITINIB
CÉRITINIB
Ceritinibum
COMPOUND 15B [PMID 23742252]
compound 15b [PMID 23742252]|LDK378|NVP-LDK378-NX|Zykadia®
|
LDK378
LDK-378
N-{2-[(5-CHLORO-2-{[2-ISOPROPOXY-5-METHYL-4-(PIPERIDIN-4-YL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENYL}PROPANE-2-SULFONAMIDE
NVP-LDK378-NX
NVP-LDK-378-NX
ZYKADIA
|
|
37 |
|
Nintedanib |
Approved |
Phase 2 |
|
656247-17-5 |
135423438 9809715 |
Synonyms:
BIBF 1120
BIBF1120
BIBF-1120
BIBF-1120|BIBF1120|Ofev®|Vargatef®
INTEDANIB
|
METHYL (3Z)-3-[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO}ANILINO)(PHENYL)METHYLIDENE]-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE
NINTEDANIB
Nintedanib esylate
Ofev
Vargatef
|
|
38 |
|
Bortezomib |
Approved, Investigational |
Phase 2 |
|
179324-69-7 |
387447 93860 |
Synonyms:
[(1R)-3-METHYL-1-({(2S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]PROPANOYL}AMINO)BUTYL]BORONIC ACID
341, PS
BORTEZOMIB
BORTEZOMIB HYDRATE
LDP 341
LDP-341
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
|
NSC-681239
PEPTIDE BORONATE
peptide boronate|PS-341|Velcade®
PS 341
PS-341
Velcade
|
|
39 |
|
Auranofin |
Approved, Investigational |
Phase 1, Phase 2 |
|
34031-32-8 |
6918453 16667669 70788951 |
Synonyms:
(1-Thio-b-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate
(1-Thio-b-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetic acid
(1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate
(1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetic acid
(1-Thio-β-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate
(1-Thio-β-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetic acid
2,3,4,6-Tetra-O-acetyl-1-thio-b-D-glucopyranosato-S (triethylphosphine)gold
2,3,4,6-Tetra-O-acetyl-1-thio-beta-D-glucopyranosato-S (triethylphosphine)gold
2,3,4,6-Tetra-O-acetyl-1-thio-β-D-glucopyranosato-S (triethylphosphine)gold
AURANOFIN
Auranofin recordati brand
Auranofin robapharm brand
Auranofin rubio brand
Auranofin yamanouchi brand
Auranofina
Auranofine
Auranofinum
|
Auroafen
Crisinor
Recordati brand OF auranofin
Ridaura
Ridaura®|SK&F-39162|SK-39162
Ridauran
Robapharm brand OF auranofin
Rubio brand OF auranofin
SK And F 39162
SK And F D 39162
SK And F39162
SK And F-39162
SK&F-39162
SK-39162
SmithKline beecham brand OF auranofin
Triethylphosphine gold
Yamanouchi brand OF auranofin
|
|
40 |
|
Lenograstim |
Approved, Investigational |
Phase 2 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
41 |
|
Picropodophyllin |
Approved, Investigational |
Phase 2 |
|
518-28-5, 477-47-4 |
10607 72435 |
Synonyms:
(−)-podophyllotoxin
(-)-Podophyllotoxin
6,7]NAPHTHO[2,3-D][1,3]DIOXOL-6(5AH)-ONE
9-HYDROXY-5-(3,4,5-TRIMETHOXYPHENYL)-5,8,8A,9-TETRAHYDROFURO[3',4'
9-HYDROXY-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-D][1,3]dioxol-6(5ah)-one
Ardern brand OF podophyllotoxin
AXL-1717
AXL1717|podofilox
Canderm brand OF podophyllotoxin
Condyline
Condylox
CPH86
Epipodophyllotoxin
Fides ecopharma brand OF podophyllotoxin
Hamilton brand OF podophyllotoxin
Newport brand OF podophyllotoxin
NSC-24818
NSC-36407
Oclassen brand OF podophyllotoxin
Paddock brand OF podophyllotoxin
Paladin brand OF podophyllotoxin
|
PICROPODOPHYLLIN
PICROPODOPHYLLOTOXIN
PODOCON-25
Podofilm
Podofilox
Podophyllinate lactone
Podophyllinic acid lactone
Podophyllotoxin
Podophyllotoxin 7
PODOPHYLLOTOXIN PICROPODOPHYLLIN
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 alpha))-isomer
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 beta))-isomer
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a beta,9 alpha))-isomer
Podophyllotoxin, (5R-(5 alpha,5a beta,8a alpha,9 beta))-isomer
PPT
Stiefel brand OF podophyllotoxin
Wartec
Warticon
Wolff brand OF podophyllotoxin
Yamanouchi brand OF podophyllotoxin
|
|
42 |
|
Metformin |
Approved |
Phase 2 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
43 |
|
Vorinostat |
Approved, Investigational |
Phase 2 |
|
149647-78-9 |
5311 |
Synonyms:
18F Suberoylanilide hydroxamic acid
18F-SAHA
18F-Suberoylanilide hydroxamic acid
Merck brand OF vorinostat
MK0683
MK-0683
MK-0683|MK0683|SAHA|suberoylanilide hydroxamic acid|Zolinza®
N Hydroxy n' phenyloctanediamide
N1 Hydroxy N8 phenyloctanediamide
N1-Hydroxy-N8-phenyloctanediamide
NHNPODA
N-Hydroxy-n'-phenyloctanediamide
N-Hyrdroxy-n'-phenyloctanediamide
|
Octanedioate hydroxyamide phenylamide
Octanedioic acid hydroxyamide phenylamide
SAHA
SHH
Suberanilohydroxamate
Suberanilohydroxamic acid
Suberoyl anilide hydroxamic acid
Suberoylanilide hydroxamate
Suberoylanilide hydroxamic acid
VORINOSTAT
Vorinostatum
Zolinza
|
|
44 |
|
Pembrolizumab |
Approved |
Phase 1, Phase 2 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
45 |
|
Fludarabine |
Approved |
Phase 1, Phase 2 |
|
75607-67-9, 21679-14-1 |
30751 657237 |
Synonyms:
2-F-ARAA
2-F-Ara-A|CCRIS 3382|F-Ara-A|Fludara®
2F-Ara-AMP
2-fluoro ARA-A
2-Fluoroadenine arabinoside 5'-monophosphate
2-Fluoroadenine arabinoside 5'-monophosphoric acid
2-Fluoro-ara AMP
2-FLUORO-ARA-A
9 beta-D-Arabinofuranosyl-2-fluoroadenine monophosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-Î’-arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-Î’-arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
|
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
Beneflur
FAMP
FaraAMP
F-Ara-AMP
Fludara
Fludarabina
FLUDARABINE
Fludarabine 5'-monophosphate
Fludarabine 5'-monophosphoric acid
Fludarabine monophosphate
Fludarabine monophosphoric acid
Fludarabine phosphate
Fludarabine phosphoric acid
Fludarabinum
Fludura
Fluoro-ara-AMP
NSC-312887
NSC-328002
OFORTA
|
|
46 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 1, Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
47 |
|
Aldesleukin |
Approved |
Phase 1, Phase 2 |
|
110942-02-4 |
|
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
Aldesleukin
Aldesleukina
IL-2
ILT101
ILT-101
Interleukin-2 aldesleukin
|
INTERLEUKIN-2 PRECURSOR
Interleukin-2(2-133),125-ser
Recombinant human interleukin-2
Recombinant interleukin-2 human
T-CELL GROWTH FACTOR
TCGF
|
|
48 |
|
Coenzyme M |
Approved, Investigational |
Phase 1, Phase 2 |
|
3375-50-6 |
598 23662354 |
Synonyms:
1-THIOETHANEsulfonate
1-THIOETHANEsulfonIC ACID
1-THIOETHANEsulphonate
1-THIOETHANEsulphonic acid
2 Mercaptoethanesulfonate
2-Mercaptoethane
2-Mercaptoethanesulfonate
2-Mercaptoethanesulfonic acid
2-Mercaptoethanesulphonate
2-Mercaptoethanesulphonate, sodium
2-Mercaptoethanesulphonic acid
2-Mercaptoethylsulfonate
2-Mercaptoethylsulfonic acid
2-Mercaptoethylsulphonate
2-Mercaptoethylsulphonic acid
2-Sulfanylethylsulfonate
2-Sulfanylethylsulfonic acid
2-Sulphanylethylsulphonate
2-Sulphanylethylsulphonic acid
ASTA D 7093
ASTA medica brand OF mesna
ASTAD 7093
ASTA-D 7093
beta-Mercaptoethanesulfonate
beta-Mercaptoethanesulfonic acid
beta-Mercaptoethanesulphonate
beta-Mercaptoethanesulphonic acid
b-Mercaptoethanesulfonate
b-Mercaptoethanesulfonic acid
b-Mercaptoethanesulphonate
b-Mercaptoethanesulphonic acid
Bristol myers squibb brand OF mesna
|
Bristol-myers squibb brand OF mesna
Cell pharm brand OF mesna
Coenzima m
Coenzym m
Coenzyme m
CoM
D-7093
HS-CoM
Kendrick brand OF mesna
Mesna
MESNA cell
Mesna kendrick brand
Mesna sanfer brand
MESNA-cell
Mesnex
Mesnum
Mistabron
Mistabronco
Mitexan
Mucofluid
NSC-113891
Reduced coenzyme m
Reduced com
Sanfer brand OF mesna
Sodium 2-mercaptoethanesulphonate
UCB brand OF mesna
Uromitexan
Ziken
Î’-mercaptoethanesulfonate
Î’-mercaptoethanesulfonic acid
Î’-mercaptoethanesulphonate
Î’-mercaptoethanesulphonic acid
|
|
49 |
|
Pemetrexed |
Approved, Investigational |
Phase 2 |
|
150399-23-8, 137281-23-3 |
60843 446556 135565230 |
Synonyms:
(2R)-2-{[4-(2-{4-hydroxy-2-imino-1H,2H,7H-pyrrolo[2,3-D]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioate
ALIMTA
Alimta®|LY-231514
Disodium, pemetrexed
LY-2315
LY231514
|
LY-231514
MTA
N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-D)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
NSC-698037
Pemetrexed
Pemetrexed disodium
|
|
50 |
|
Cisplatin |
Approved |
Phase 2 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
Interventional clinical trials:
(show top 50)
(show all 113)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Apatinib Mesylate Was Used in the Treament of Patients With Advanced Lung Squamous Cell Carcinoma of the Third Line and Above |
Unknown status |
NCT03725423 |
Phase 4 |
Apatinib |
2 |
An Open-label, Single-arm Clinical Study to Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation |
Unknown status |
NCT04132102 |
Phase 4 |
Afatinib |
3 |
Nedaplatin (Jiebaishu®) and Docetaxel in Comparison With Cisplatin and Docetaxel Regimen for the First Line Treatment of Advanced Squamous Cell Carcinoma of Lung(IIIB/IV): Randomized, Controlled, Multicentre Study |
Completed |
NCT02088515 |
Phase 4 |
Nedaplatin;Cisplatin;Docetaxel |
4 |
Evaluation of the Benefits of Oral Metronomic Cyclophosphamide in Combination With Standard Cisplatin-etoposide Based Chemotherapy for Squamous Cell Lung Carcinoma |
Unknown status |
NCT01947062 |
Phase 3 |
Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide |
5 |
The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration. |
Unknown status |
NCT02283476 |
Phase 3 |
Endostar continuous intravenous infusion;Endostar routine intravenous infusion;Gemcitabine;Cisplatin |
6 |
Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer :A Randomized, Open, Parallel, Multicentre, Phase â…¢ Study |
Unknown status |
NCT02643407 |
Phase 3 |
Docetaxel;Nedaplatin;Cisplatin |
7 |
A Phase III, Randomized, Double-blinded, Multicenter Study of AK105 Combined With Carboplatin and Paclitaxel vs Placebo Combined With Carboplatin and Paclitaxel as First-line Therapy in Patients With Metastatic Squamous Non-small Cell Lung Cancer |
Unknown status |
NCT03866993 |
Phase 3 |
Paclitaxel;Carboplatin;Placebo |
8 |
A Phase II Study of MEDI4736 for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Lung-Map Sub-Study) |
Completed |
NCT02766335 |
Phase 2, Phase 3 |
Docetaxel |
9 |
A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) |
Completed |
NCT02965378 |
Phase 2, Phase 3 |
Docetaxel;FGFR Inhibitor AZD4547 |
10 |
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) |
Completed |
NCT02785939 |
Phase 2, Phase 3 |
Docetaxel;Palbociclib |
11 |
A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy With ZD1839 (NSC-715055) or Placebo in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer |
Completed |
NCT00020709 |
Phase 3 |
cisplatin;docetaxel;etoposide;gefitinib |
12 |
Multicenter, Open-Ended, Double-Blind, Placebo-Controlled, Phase III Study of AE-941 in Addition to Combined Modality Treatment (Chemotherapy/Radiotherapy) for Locally Advanced Unresectable Non-Small Cell Lung Cancer |
Completed |
NCT00005838 |
Phase 3 |
shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel |
13 |
A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG |
Completed |
NCT00002852 |
Phase 3 |
paclitaxel;carboplatin |
14 |
A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer |
Completed |
NCT00049543 |
Phase 3 |
gefitinib |
15 |
Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) |
Completed |
NCT01082549 |
Phase 3 |
gemcitabine/carboplatin;gemcitabine/carboplatin plus Iniparib |
16 |
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study) |
Active, not recruiting |
NCT02785952 |
Phase 3 |
|
17 |
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
NCT00946712 |
Phase 3 |
Carboplatin;Paclitaxel |
18 |
Efficacy and Safety Evaluation of IBI308 Versus Docetaxel in Patients With Advanced or Metastatic Squamous Cell Lung Cancer After Failure of First-line Platinum-based Therapy- a Randomized, Open-label, Multicenter, Parallel, Phase 3 Study (ORIENT-3) |
Active, not recruiting |
NCT03150875 |
Phase 3 |
IBI308;Docetaxel |
19 |
A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib Versus Erlotinib as Second Line Therapy for C-Met Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) |
Terminated |
NCT02926638 |
Phase 2, Phase 3 |
Erlotinib Hydrochloride |
20 |
Photodynamic Therapy for the Prevention of Lung Cancer (PEARL) |
Withdrawn |
NCT03346304 |
Phase 2, Phase 3 |
|
21 |
An Open-label, Single-armed Pilot Study to Evaluate the Efficacy of Icotinib in Previously Treated Non/Light-smoking Patients With Squamous Lung Cancer |
Unknown status |
NCT02009605 |
Phase 2 |
Icotinib |
22 |
A Phase II Trial of Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer After Failure of Platinum Doublet (Except Pemetrexed) Therapy |
Unknown status |
NCT01969955 |
Phase 2 |
nanoparticle albumin-bound paclitaxel |
23 |
Boanmycin Hydrochloride for Injection in Combination With Docetaxel for Patients With Advanced Lung Squamous Cell Carcinoma as Salvage Chemotherapy: a Prospective, Randomized, Parallel and Controlled Clinical Trial |
Unknown status |
NCT01660399 |
Phase 2 |
Boanmycin;Docetaxel |
24 |
Phase II Study of Afatinib Plus Chemotherapy in Patients With Esophageal and Lung Squamous Cell Carcinoma |
Unknown status |
NCT03486509 |
Phase 2 |
Afatinib |
25 |
A Multicenter Phase II Trial of Induction Nimotuzumab Plus Gemcitabine and Carboplatin Followed by Surgery in Patients With Unresectable Stage III Squamous Cell Lung Carcinoma |
Unknown status |
NCT02428764 |
Phase 2 |
Nimotuzumab;Gemcitabine;Carboplatin |
26 |
A Phase Ib/IIa Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers |
Unknown status |
NCT02583542 |
Phase 1, Phase 2 |
AZD2014;AZD6244 |
27 |
A Prospective Phase II, Randomized Multi-center Trial of a Combined Modularized Treatment With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Nivolumab in Patients With Squamous Cell Lung Cancer and Non- Squamous Cell Lung Cancer, Respectively After Platin Failure |
Unknown status |
NCT02852083 |
Phase 2 |
Pioglitazone;nivolumab;Treosulfan;Clarithromycin |
28 |
SQUINT (Squamous Immunotherapy Nivolumab-Ipilimumab Trial): An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) |
Unknown status |
NCT03823625 |
Phase 2 |
Nivolumab plus Ipilimumab;Platinum-based chemotherapy plus Nivolumab |
29 |
A Phase II Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Every-21-Day Docetaxel Consolidation in Patients With Inoperable Stage IIIA/B Squamous Cell Lung Cancer |
Unknown status |
NCT02787473 |
Phase 2 |
pemetrexed;cisplatin;docetaxel |
30 |
A Phase II Study of Concurrent Nab-Paclitaxel, Carboplatin and Thoracic Radiotherapy in Local Advanced Squamous Cell Lung Cancer |
Unknown status |
NCT01494415 |
Phase 2 |
Paclitaxel for Injection(Albumin Bound);carboplatin |
31 |
A Phase II Trial to Evaluate Efficacy and Safety of Erdafitinib in Patients With Advanced Squamous Non Small Cell Lung Carcinoma (sqNSCLC) Harboring Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations After Relapse of Standard Therapy. |
Unknown status |
NCT03827850 |
Phase 2 |
ERDAFITINIB |
32 |
A Phase II Randomised, Open-label Study of Gemcitabine/Carboplatin First-line Chemotherapy in Combination With or Without the Antisense Oligonucleotide Apatorsen (OGX-427) in Advanced Squamous Cell Lung Cancers |
Unknown status |
NCT02423590 |
Phase 2 |
Apatorsen (OGX-427);Gemcitabine;Carboplatin |
33 |
A Randomized Phase II Clinical Trial of Nab-Paclitaxel and Carboplatin Compared With Gemcitabine and Carboplatin as First-line Therapy in Advanced Squamous Cell Carcinoma of Lung |
Completed |
NCT01236716 |
Phase 2 |
Albumin paclitaxel plus carboplatin;Gemcitabine plus carboplatin |
34 |
A Phase 2 Study of MLN0128 (TAK-228) in Patients With Advanced Non-Small Cell Lung Cancers Harboring NFE2L2 and KEAP1 Mutations |
Completed |
NCT02417701 |
Phase 2 |
Sapanisertib |
35 |
A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma |
Completed |
NCT01807546 |
Phase 2 |
rigosertib |
36 |
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study) |
Completed |
NCT02785913 |
Phase 2 |
Taselisib |
37 |
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) |
Completed |
NCT03377556 |
Phase 2 |
Talazoparib |
38 |
A Phase II Study of ABBV-399 in Patients With C-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP SUB-STUDY) |
Completed |
NCT03574753 |
Phase 2 |
ABBV-399 |
39 |
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study) |
Completed |
NCT03373760 |
Phase 2 |
|
40 |
A Phase II, Open Label, Multiple Arm Study of Single Agent AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (NSCLC) |
Completed |
NCT02276027 |
Phase 2 |
BYL719;INC280;LDK378;MEK162 |
41 |
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy |
Completed |
NCT01294306 |
Phase 2 |
Akt Inhibitor MK2206;Erlotinib Hydrochloride |
42 |
A Phase II Trial of TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Carcinoma of the Lung |
Completed |
NCT02920476 |
Phase 2 |
TAS-102 |
43 |
A Prospective Randomized Phase â…¡ Study of Nimotuzumab Combined With Chemoradiotherapy for Unresectable, Locally Advanced Squamous Cell Lung Cancer |
Completed |
NCT02577341 |
Phase 2 |
Nimotuzumab;docetaxel and cisplatin |
44 |
FGFR1 Amplification as A Predictor of Efficacy in A Biomarker-Driven Phase II Study of BIBF 1120 in Advanced Squamous Cell Lung Cancer Patients Who Have Failed Up to Two Prior Chemotherapeutic Regimens |
Completed |
NCT01948141 |
Phase 2 |
nintedanib |
45 |
AVF4236s: Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer |
Completed |
NCT00585377 |
Phase 2 |
Bevacizumab and Erlotinib |
46 |
A Phase II Study of Prophylactic Radiation Therapy for the Prevention of Hemoptysis in Advanced Non Small Cell Lung Cancer in Combination With Bevacizumab, Paclitaxel, and Carboplatin in Patients at High Risk for Bevacizumab-Associated Hemoptysis |
Completed |
NCT00387374 |
Phase 2 |
paclitaxel;carboplatin |
47 |
Phase II Trial of OSI-774 (NSC-718781) in Patients With Advanced Non-Small Cell Lung Cancer and a Performance Status of 2 |
Completed |
NCT00087412 |
Phase 2 |
erlotinib hydrochloride |
48 |
A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed By Cetuximab and Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
NCT00368992 |
Phase 2 |
paclitaxel |
49 |
ZD1839 (NSC #715055, IND #61187) With Induction Paclitaxel And Carboplatin Followed By Either Radiation Or Concomitant Radiation With Weekly Paclitaxel And Carboplatin In Stage III Non-Small Cell Lung Cancer, A Phase II Study |
Completed |
NCT00040794 |
Phase 2 |
paclitaxel;carboplatin;gefitinib |
50 |
A Phase II Trial of Docetaxel Plus Cetuximab and Docetaxel Plus Bortezomib (NSC #681239, IND #58443) in Advanced Non-Small Cell Lung Cancer Patients With Performance Status (PS) 2 |
Completed |
NCT00118183 |
Phase 2 |
docetaxel;bortezomib |
|